Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip GmbhfiledCriticalBayer Ip Gmbh
Priority to HN2010001125ApriorityCriticalpatent/HN2010001125A/en
Publication of HN2010001125ApublicationCriticalpatent/HN2010001125A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A NUEVOS DERIVADOS DE 4-(4-CIANO-2-TIOARIL)DIHIPROPIRIMIDIN-2-ONA, A PROCEDIMIENTOS PARA SU PREPARACION, A SU USO SOLOS O EN COMBINACIONES PARA EL TRATAMIENTO Y/O LA PREPARACION DE ENFERMEDADES, ASI COMO A SU USO PARA LA PREPARACION DE MEDICAMENTOS PARA EL TRATAMIENTO Y/O LA PREVENCION DE ENFERMEDADES, PARTICULARMENTE PARA EL TRATAMIENTO Y/O LA PREVENCION DE ENFERMEDADES PULMONARES Y DEL SISTEMA CARDIOCIRCULATORIO.THIS INVENTION REFERS TO NEW DERIVATIVES OF 4- (4-CIANO-2-TIOARIL) DIHIPROPIRIMIDIN-2-ONA, TO PROCEDURES FOR THEIR PREPARATION, FOR USE ONLY OR IN COMBINATIONS FOR THE TREATMENT AND / OR PREPARATION OF DISEASES, AS WELL AS FOR ITS USE FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT AND / OR THE PREVENTION OF DISEASES, PARTICULARLY FOR THE TREATMENT AND / OR THE PREVENTION OF PULMONARY DISEASES AND THE CARDIOCIRCULATORY SYSTEM.
HN2010001125A2010-06-022010-06-02
4- (4-CIANO-2-TIOARIL) DIHYDROPIRIMIDINONES AND ITS USE
HN2010001125A
(en)
Compounds derived from spiro- [1,3] -oxacins and spiro- [1,4] -oxacepins, inhibitors of bace1 and / or bace2; pharmaceutical composition; procedure to prepare them; and its use in the treatment and / or prophylaxis of Alzheimer's disease and diabetes.
Compounds derived from 2,3-dihydromidazo (1,2-c) quinazoline substituted with amino alcohols; intermediate compound and its use; pharmaceutical composition; pharmaceutical combination; and its use to treat hyperproliferative disorders and diseases associated with angiogenesis.
Compound 4-hydroxy-2-methyl-5- (propan-2-ylidene) cyclohexyl-3-en-1-carbaldehyde; use of the compound for the treatment of Alzheimer's disease; pharmaceutical composition; Method to prepare the composition.